Friday, September 13, 2013
Takeda To Sell Rights To Blood Pressure Drugs To U.S. Firm
TOKYO (Nikkei)--Takeda Pharmaceutical Co. (4502) said Friday it will sell the U.S. development and marketing rights to two high-blood-pressure treatments to American drugmaker Arbor Pharmaceuticals LLC.
The Japanese drugmaker will receive about 9 billion yen in exchange for the rights to Edarbi and Edarbyclor in addition to royalties on future sales of the products.
Takeda has been selling Edarbi in the U.S. since 2011. It has recently released a diabetes drug there and has plans to launch medications for ulcerative colitis, major depression, obesity and other disorders next year and afterward. The company decided to sell the rights to the blood pressure drugs to focus on these new products.
(The Nikkei, Sept. 14 morning edition)